Skip to main content

Table 1 Patients' characteristics.

From: A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome

 

Patient number (%)

 

Characteristic

LG group

AG group

ALG group

Pvalue

Patient treated

10

16

16

-

Age

   

-

Median

51.5

55

51.5

 

Range

27~75

23~71

34~87

 

Sex

   

0.694

Male

7(70%)

9 (56.3%)

11(68.8%)

 

Female

3(30%)

7 (43.7%)

5(31.2%)

 

Primary tumor site

   

0.711

Gastro

6 (60%)

9 (56.3%)

8(50%)

 

Small intestine

2 (20%)

4 (25%)

3(18.8%)

 

Colon

2 (20%)

2 (12.5%)

3(18.8%)

 

Rectum

0

1 (6.2%)

0

 

Mesentery

0

0

2(12.5%)

 

Recurrent-free time from surgery

   

-

Median (month)

15.5

12

24

 

Range (month)

9~108

2~100

3~108

 

ECOG performance status

   

0.815

0

3 (30%)

4 (25%)

6(37.5%)

 

1

6(60%)

9 (56.3%)

9(56.3%)

 

2

1 (10%)

2 (12.5%)

0

 

3

0

1 (6.2%)

1(6.2%)

 

Biomarker

    

CD117 positive

10 (100%)

16 (100%)

16(100%)

-

CD34 positive

7 (70%)

12 (75%)

14(87.5%)

0.518

Aggressive behavior

   

0.492

Very low & low risk

4(40%)

4(25%)

8(50%)

 

Intermediate risk

2(20%)

2(12.5%)

3(18.8%)

 

High risk

4(40%)

10(62.5%)

5(31.2%)

 
  1. LG: Recurrent liver GISTs
  2. AG: Recurrent abdominal GISTs
  3. ALG: Recurrent abdominal and liver GISTs